Remove Patients Remove Pharmaceutical research Remove Prescription
article thumbnail

The Dark Side of the Pharmaceutical Industry: Are Treatments Being Blocked for Profit?

Pharma Marketing Network

This involves paying researchers and scientists to publish articles or conduct studies that support the use of a particular drug, while suppressing or ignoring research that casts doubt on the drug’s safety or efficacy. Pharmaceutical research and development: what do we get for all that money? W., & Lexchin, J.

article thumbnail

And so pharma profiteers again

World of DTC Marketing

One of the biggest problems with a system that directs medical research towards profits rather than needs is that R&D funding is channelled to those products that can make pharma companies the most money. The best prospects are drugs targeted at patients who are high-value and who will use the drugs long term.

Pharma 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Beating the Big C

Pharmaceutical Technology

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.

article thumbnail

PhRMA is going to have to write some big checks

World of DTC Marketing

SUMMARY: President Biden wants to lower prescription drug costs. Even though prescription drug costs are only $.11 The Pharmaceutical Research and Manufacturers of America raised nearly $527 million last year and spent roughly $506 million, new tax returns obtained by OpenSecrets reveal.

article thumbnail

US Democrats’ blockbuster budget bill could spell big changes for drug prices

pharmaphorum

In addition to the climate provisions, however, the bill has a significant effect on prescription drug prices, and according to reports neither Manchin nor Sinema is objecting to these provisions, which are similar but not identical to the ones in the Build Back Better plan which previously passed in the House of Representatives.